Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 4/20 | 0.33 |
| ▸ | SAT1 | P21673 | 2/20 | 0.31 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.31 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22799575 | 0.86 | CYP2C19 (0.39) | CYP2C19CYP1A2MEN1GLAKMT2A | |
| SCHEMBL21081696 | 0.85 | CYP2C19 (0.38) | CYP2C19CYP1A2MEN1GLAKMT2A | |
| SCHEMBL24220974 | 0.85 | CYP2C19 (0.38) | CYP2C19CYP1A2MEN1GLAKMT2A | |
| SCHEMBL26231094 | 0.84 | KISS1R (0.41) | — | |
| SCHEMBL13468552 | 0.84 | KISS1R (0.41) | — | |
| SCHEMBL18806451 | 0.82 | CYP2C19 (0.41) | CYP2C19CYP1A2MEN1GLAKMT2A | |
| SCHEMBL22062262 | 0.82 | CA1 (0.44) | MEN1KMT2A | |
| SCHEMBL14712334 | 0.81 | CYP2C19 (0.40) | CYP2C19CYP1A2MEN1GLAKMT2A | |
| SCHEMBL25132732 | 0.81 | KDM4E (0.35) | — | |
| SCHEMBL21089909 | 0.77 | DPP7 (0.42) | CYP2C19CYP1A2MEN1GLAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023057813-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |